Why should I take Nolvadex?

admin   February 5, 2016   Comments Off on Why should I take Nolvadex?

Nolvadex

PACKAGING

Nolvadex presented as tablets containing tamoxifen citrate (Brit.Farm.) In an amount equivalent to 10 mg tamoxifen.

Nolvadex D-represented in the form of tablets comprising tamoxifen citrate (Brit.Farm.) In an amount equivalent to 20 mg tamoxifen.

Nolvadex Forte presented as tablets containing tamoxifen citrate (Brit.Farm.) In an amount equivalent to 40 mg tamoxifen.

INDICATIONS

Nolvadex indicated for the treatment of breast cancer.

PROPERTIES

Nolvadex (Tamoxifen) is antiestrogen nesteroidym. In humans Nolvadex acts mainly as an antiestrogen inhibiting endogenous estrogen exposure, probably by binding to estrogen receptors.

However, clinical data show a slight beneficial effect of the drug on the ER-negative tumors, which gives grounds for assuming the existence of other mechanisms of action. Details

It is a recognized fact that tamoxifen has estrogen-like effect on a number of body systems, including endometrium, bone, and blood lipids.

After oral alpha pharma nolvadex rapidly absorbed, and maximum serum concentrations achieved within 4-7 hours.

Stable concentrations (approximately 300 ng / ml) were achieved after four weeks of treatment with a daily 40 mg dose of reception. The drug binds well to serum albumin (> 99%). As a result of metabolism in the process of hydroxylation and conjugation demethylation, formation takes place of several metabolites that are indicators pharmacological profile similar to the starting chemical compound, thus, contributes to the therapeutic effect. Isolation occurs mainly via feces. The half-life for the drug itself has been set at about seven days, while for the X-desmetiltamoksifena, the main circulating metabolite of 14 days.

DOSAGE AND RECEPTION

For adults (including the elderly); The daily dose is between 20 and 40 mg doses taken or divided twice daily or a single daily dose.

CONTRAINDICATIONS

Nolvadex should not be used during pregnancy. There are few reports on cases of spontaneous abortions, birth defects and fetal deaths after women receiving the drug Nolvadex, although a causal relationship has not been established.

Research in the field of reproductive toxicology, conducted with the participation of rats, rabbits and monkeys have shown no teratogenic potential.

In individuals rodents studied for fetal reproductive tract development, tamoxifen was associated with changes similar to those that are caused by exposure to estradiol, ethinyl estradiol, clomiphene and dietilstilbastrola (DES). Although the clinical correlation of these changes is unknown, some of them (especially vaginal adenosis), similar to that observed in young women who were exposed to DES in utero and in 1 of 1,000 cases of clear risk of occurrence of cancer of the vagina or cervix. Only a small number of pregnant women exposed to tamoxifen. In these cases, there are no reports that such exposure is the cause of the subsequent occurrence of vaginal adenosis or clear-vaginal or cervical cancer in young women exposed to tamoxifen.

In cases of sexual activity while using the drug Nolvadex women should be advised to prevent pregnancy and to use barrier or other non-hormonal contraceptive. Before starting the treatment of patients in the pre-menopausal, they should carefully examine, in order to exclude the presence of pregnancy. Women should assess the potential risk to the fetus in cases where pregnancy occurs during use of the drug Nolvadex or within two months after discontinuation of therapy. Stanozolol for sale by Alpha-Pharma Steroids representative.

CAUTIONS

A number of women receiving Nolvadex for the treatment of breast cancer in predklemaktericheskom period, there is a lack of menstruation.

Use of the drug in combination with Nolvadex coumarin anticoagulants type can cause considerable increase anticoagulant action. In cases where there is simultaneous use of these drugs, it is recommended to closely monitor the patient.

When applied in combination with Nolvadex cytotoxic agents have an increased risk of thromboembolic events.

In connection with the treatment of drug Nolvadex noted an increased incidence of endometrial changes including hyperplasia, polyps and cancer. The frequency and pattern of this increase suggest that the underlying mechanism of the estrogen-related properties of Nolvadex. All earlier decision or taking Nolvadex patients in which there is abnormal vaginal bleeding, should be subject to the timely examination. Details

Tamoxifen did not show itself as a mutagenic agent in a series carried out in vitro and in vivo tests for mutagenicity. Tamoxifen provided genotoxic effect at the time of some in vitro experiments and tests for genotoxicity in vivo in rodents. During long-term studies were established facts gonadal tumors in mice and liver tumors in rats receiving tamoxifen. Clinical correlation of this data has not been established.

In clinical studies carried out after the treatment of patients with breast cancer with tamoxifen, it has been a number of second primary tumors arising in other than in the opposite enometrii and chest areas. A causal relationship has not been established, and the clinical significance of these observations remains unclear.

Lactation: Data on the allocation of Nolvadex into breast milk in the absence of women, therefore its use during lactation is not recommended. The decision to terminate or feeding, or the drug Nolvadex, must proceed from the importance of its application to the mother.

SIDE EFFECTS

Prolonged treatment side effects are not as numerous or not so serious in cases where the drug Nolvadex, as in the case of androgen and estrogen, which are also used to treat breast cancer. Observed side effects can be classified as emerging or by antiastrogennogo of the drug, such as hot flushes, vaginal bleeding, vaginal discharge and itching of the vulva, or as side effects of a more general nature, such as gastrointestinal intolerance, retsidirovanie swelling, dizziness , skin rash, and in some cases, fluid retention and alopecia.

In case of serious side effects control of them may be carried out by simple dose reduction, while maintaining control over the course of the disease. A small number of patients with bone metastases were observed during methocarbamol side effects the treatment of hypercalcemia.

Patients who use Nolvadex for the treatment of breast cancer, is usually marked decrease in platelet count to 80,000 -. 90,000 per cubic mm, and sometimes even lower. A number of patients who use Nolvadex, marked impairment, including rare cases of corneal changes, cataracts and retinopathy.

cases of uterine fibroids were noted.

From time to time we observed cystic swelling of the ovaries in women who use Nolvadex premenopausal.

After applying the drug Nolvadex leukopenia observed cases, sometimes due to anemia and / or thrombocytopenia. Neutropenia was observed in rare cases; sometimes it can be severe.

During therapy with Nolvadex were rare cases of thromboembolic events. Although it is known that these phenomena are more frequent in patients with malignant course of disease, a causal relationship with Nolvadex has not been established.

When applied in combination with Nolvadex cytotoxic agents have an increased risk of thromboembolic events.

The use of Nolvadex is associated with changes in liver enzyme levels, and in rare cases, more serious disorders, including fatty liver, cholestasis and hepatitis.

OVERDOSE

Theoretically, an overdose can be expected strengthening of anti-estrogen side effects mentioned above. The observations in animals suggest that excessive overdose (100-200 times higher than the recommended daily dose) may cause estrogenic action. There is no specific antidote, and treatment should be symptomatic.

PHARMACEUTICAL PRECAUTIONS

Store at room temperature, protected from light.

FURTHER INFORMATION

Effects on ability to drive or operate machinery: The facts of violation of these activities with Nolvadex is not available.